Puzzle Medical Devices Inc. announces the closing of its major Seed financing round to support its first-in-human study
Summary
The companys focus is entirely consistent with Broadviews mission to accelerate the development of promising technologies for the treatment of cardiovascular disease and stroke, and we look forward to supporting Puzzle Medicals management team as it advances this important technology.In support of this Seed investment, David Prim, PhD will be joining the Puzzle Medical Board of Directors to represent Broadview Ventures, bringing with him a background in biomedical research, strategy and dealmaking. This greatly strengthens Puzzle Medicals capability and focus to achieve its north star which is to improve HF patients quality of life, said Jade Doucet-Martineau, co-founder and CEO of Puzzle Medical.Puzzle Medical designed the ModulHeart device as a treatment for patients with advanced HF who are not heart transplant or surgical MCS candidates. The novel design will allow safe long-term implantation, with low risk of bleeding, stroke, and pump thrombosis, thereby providing sustained symptom relief and improved overall quality of life.Managing patients with advanced HF has always been challenging. Currently, the field of therapeutic device development for patients with acute and chronic HF is booming, said Dr Daniel Burkhoff, Clinical Advisor of Puzzle Medical. Broadview is an affiliate of the Leducq Foundation.Puzzle Medical Devices Inc. (www.puzzlemed.com) is developing ModulHeart, a percutaneous heart pump for patients with advanced HF.